ATE152174T1 - Verfahren zur herstellung von fusionsproteinen - Google Patents

Verfahren zur herstellung von fusionsproteinen

Info

Publication number
ATE152174T1
ATE152174T1 AT90913419T AT90913419T ATE152174T1 AT E152174 T1 ATE152174 T1 AT E152174T1 AT 90913419 T AT90913419 T AT 90913419T AT 90913419 T AT90913419 T AT 90913419T AT E152174 T1 ATE152174 T1 AT E152174T1
Authority
AT
Austria
Prior art keywords
dna sequence
transfected
fusion proteins
restriction site
splice site
Prior art date
Application number
AT90913419T
Other languages
English (en)
Inventor
Stephen D Gillies
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE152174T1 publication Critical patent/ATE152174T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/461Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT90913419T 1989-09-20 1990-08-01 Verfahren zur herstellung von fusionsproteinen ATE152174T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40988989A 1989-09-20 1989-09-20

Publications (1)

Publication Number Publication Date
ATE152174T1 true ATE152174T1 (de) 1997-05-15

Family

ID=23622388

Family Applications (2)

Application Number Title Priority Date Filing Date
AT96113414T ATE228566T1 (de) 1989-09-20 1990-08-01 Verfahren zur herstellung von fusionsproteinen
AT90913419T ATE152174T1 (de) 1989-09-20 1990-08-01 Verfahren zur herstellung von fusionsproteinen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT96113414T ATE228566T1 (de) 1989-09-20 1990-08-01 Verfahren zur herstellung von fusionsproteinen

Country Status (9)

Country Link
EP (2) EP0765937B1 (de)
JP (1) JP3051162B2 (de)
AT (2) ATE228566T1 (de)
AU (1) AU633357B2 (de)
CA (1) CA2066612C (de)
DE (2) DE69030579T2 (de)
DK (2) DK0765937T3 (de)
ES (2) ES2187598T3 (de)
WO (1) WO1991004329A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5498538A (en) * 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
US5747334A (en) * 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
DE69133054T2 (de) * 1990-10-22 2002-11-14 Genentech Inc Verfahren zur modifizierung von dna und zur detektion der wirkungen auf die interaktion von modifizierten polypeptiden und zielsubstraten
US5525491A (en) * 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
US6103521A (en) * 1995-02-06 2000-08-15 Cell Genesys, Inc. Multispecific chimeric receptors
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
DK1196566T3 (da) * 1999-07-12 2006-06-06 Genentech Inc Ekspressionsvektorer og -metoder
DK1200479T3 (da) 1999-08-09 2006-05-15 Emd Lexigen Res Ct Corp Multiple cytokin-antistof-komplekser
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
AU2002248571B2 (en) 2001-03-07 2007-01-18 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
WO2005070967A2 (en) 2004-01-22 2005-08-04 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
UA97469C2 (uk) 2005-07-25 2012-02-27 Емерджент Продакт Дівелопмент Сіетл, Елелсі Гуманізована специфічна до cd37 зв'язувальна молекула імуноглобуліну
CN101351477B (zh) 2005-12-30 2011-11-16 默克专利有限公司 具有降低的免疫原性的抗cd19抗体
PL1966238T3 (pl) 2005-12-30 2012-09-28 Merck Patent Gmbh Warianty interleukiny-12p40 o polepszonej stabilności
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
NZ603059A (en) 2008-04-11 2014-07-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US10071748B2 (en) 2015-09-17 2018-09-11 Sony Corporation System and method for providing driving assistance to safely overtake a vehicle
US11352426B2 (en) 2015-09-21 2022-06-07 Aptevo Research And Development Llc CD3 binding polypeptides
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CN110592057B (zh) * 2019-09-27 2022-01-28 昆明理工大学 嵌合裂解酶ILTphg和编码此酶的多核苷酸

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4771002A (en) * 1984-02-24 1988-09-13 Lubrizol Genetics, Inc. Transcription in plants and bacteria

Also Published As

Publication number Publication date
EP0765937A1 (de) 1997-04-02
DE69030579T2 (de) 1997-11-13
EP0493418A4 (en) 1992-09-02
EP0493418A1 (de) 1992-07-08
WO1991004329A1 (en) 1991-04-04
EP0493418B1 (de) 1997-04-23
ES2187598T3 (es) 2003-06-16
EP0765937B1 (de) 2002-11-27
CA2066612A1 (en) 1991-03-21
DE69034022T2 (de) 2003-07-10
DK0765937T3 (da) 2003-03-24
AU6335290A (en) 1991-04-18
DE69034022D1 (de) 2003-01-09
JP3051162B2 (ja) 2000-06-12
DE69030579D1 (de) 1997-05-28
DK0493418T3 (da) 1997-11-03
CA2066612C (en) 1998-12-08
ATE228566T1 (de) 2002-12-15
JPH05500310A (ja) 1993-01-28
AU633357B2 (en) 1993-01-28
ES2103274T3 (es) 1997-09-16

Similar Documents

Publication Publication Date Title
ATE228566T1 (de) Verfahren zur herstellung von fusionsproteinen
AU2894289A (en) Domain-modified constant region antibodies
MY157028A (en) Mammalian cytokine, related reagents
ATE231523T1 (de) Osteogene vorrichtungen
NL300197I1 (de)
PT83065A (de) Fusionsproteine verfahren zu ihrer herstellung und ihre verwendung
YU150891A (sh) Rekombinantna genetska informacija
FI864624A (fi) Bombyx morin nuclear polyhedrosis -yhdistelmävirus ja menetelmiä proteiinien valmistamiseksi tätä käyttäen
DE3683447D1 (de) Verfahren zur herstellung von humanlysozym.
AU6989687A (en) Preparation of factor XIIIa by gene manipulation
ATE265533T1 (de) Saeugetierchemokine
PT97427A (pt) Processo para a preparacao de proteinas de fusao de tendamistato em estreptomicetas
MX9603266A (es) Genes de timocina de mamiferos.
ATE346919T1 (de) Nebenhoden-spezifisches rezeptorprotein und dessen verwendung
PT81253B (pt) Processo para a preparacao de uma sequencia de sinal sintetica para o transporte de proteinas em sistemas de expressao
NO173194C (no) Fremgangsmaate for fremstilling av proinsulin
IE881338L (en) A process for the preparation of foreign proteins in¹streptomycetes
WO2000034335A3 (en) 'death domain' containing receptors
AR002004A1 (es) Proteina slam, anticuerpo o un fragmento del mismo que se fija a dicha proteina, metodo de purificacion, acido nucleico que codifica dicha proteina,vector de expresion, equipo que la contiene, metodo de deteccion, metodo de modulacion y metodo para preparar una composicion farmaceutica.
DE68917520D1 (de) Verfahren und Systeme zur Herstellung von HIV-Antigenen.
KR890013177A (ko) 신규폴리펩티드 및 그것을 코우드하는 dna
DK0487229T3 (da) DNA, der koder for et protein, som binder til enhanceren for alfa-føtoproteingenet
AU7737487A (en) DNA coding for antigen protein of rinderpest virus

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee